McKesson nets 44 deals for molecular, genetic tests

Forty-four managed care organizations have licensed McKesson's molecular and genetic diagnostic management technologies, including recent new health plan customers Molina Healthcare, Paramount Healthcare and Providence Health Plans, part of the five-state Providence Health & Services.

San Francisco-based McKesson said its molecular and genetic testing management offerings include InterQual Molecular Diagnostic Criteria, Clear Coverage, Clear Orders and analytics services. This combination provides evidence-based clinical decision support for more than 500 molecular and genetic tests.

The Clear Coverage and Clear Orders tools automate notifications and authorizations while giving providers access to medical, network and benefit policies, as well as validating coverage prior to testing and forward orders to appropriate labs. InterQual Criteria clinical decision support content is included in Clear Coverage to provide medical necessity guidelines based on evidence-based medicine.

 

 

 

 

Around the web

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.

Philips is recalling the software associated with its Mobile Cardiac Outpatient Telemetry devices after certain high-risk ECG events were never routed to trained cardiology technicians as intended. The issue, which lasted for two years, has been linked to more than 100 injuries. 

Heart Rhythm Society President Kenneth A. Ellenbogen, MD, detailed a new advocacy group focused on improving EP reimbursements, patient care and access. “If you’re not at the table, you’re on the menu," he said.